Our expertise extends to leveraging cutting-edge technologies such as mass spectrometry-based proteomics, next-generation sequencing (NGS), and bioinformatics analysis to uncover new diagnostic, prognostic, and predictive biomarkers.
Learn More →Creative Biolabs offers precise quantification of NY-ESO-1 expression at both mRNA and protein levels, detailed characterization of anti-NY-ESO-1 humoral and cellular immune responses, and in-depth analysis of T-cell specificity and function. Our services are tailored to support biomarker discovery and the evaluation of therapeutic efficacy in vaccine development, adoptive cell therapies, and combination treatments. Creative Biolabs ensures reliable, reproducible data to guide your critical decisions.
NY-ESO-1 (New York esophageal squamous cell carcinoma 1), as a member of the cancer-testis antigen (CTA) family, is widely considered to be a good candidate target for immunotherapy because its restricted expression profile in healthy adult tissues effectively reduces the risk of off-target toxicity. To date, NY-ESO-1 targeted therapies have come a long way, targeting the antigen using a series of approaches from peptide and protein vaccinations, antibodies, adoptive T cell therapies, to combinational treatment modalities.
Discover how we can help - Request a consultation.
Fig.1 NY-ESO-1 targeted approaches for cancer immunotherapy.1
| In Vitro Assays | In Vivo Assays |
|---|---|
|
|
Our seasoned scientists possess the profound scientific insights necessary to navigate the complexities of NY-ESO-1 immunology and deliver exceptional results, ensuring your research is guided by the best in the field.
Our commitment to scientific excellence is underpinned by state-of-the-art laboratory instrumentation and rigorously validated protocols, ensuring that your projects benefit from the most advanced analytical capabilities, delivering highly precise and accurate data.
Creative Biolabs adheres to stringent quality control measures throughout every stage of the assay process, from sample handling to data analysis, guaranteeing the generation of consistently robust and reproducible results.
Our comprehensive service is designed to accelerate your journey from discovery to application. We empower you to make informed decisions faster, ultimately streamlining your path to bringing life-changing discoveries to the field.
Experience the Creative Biolabs advantage - Get a quote today.
We accept a wide range of biological samples, including fresh or frozen tumor tissues, which can be provided as FFPE blocks for immunohistochemistry or fresh biopsies for molecular analysis. We also routinely process peripheral blood mononuclear cells (PBMCs) for detailed cellular immune profiling, as well as serum and plasma for the detection of circulating antibodies and other soluble biomarkers.
Our NY-ESO-1 assays are rigorously validated through a multi-tiered quality control system. We utilize cutting-edge, state-of-the-art instrumentation, which is regularly calibrated and maintained to industry standards. Furthermore, all assays are performed by highly trained and experienced scientists who adhere strictly to robust standard operating procedures.
Our service offers significant advantages over establishing and running these complex assays in-house. We provide immediate access to advanced technologies, high-throughput capabilities, and expert interpretation that might be costly or time-consuming to establish internally.
Our expertise extends to leveraging cutting-edge technologies such as mass spectrometry-based proteomics, next-generation sequencing (NGS), and bioinformatics analysis to uncover new diagnostic, prognostic, and predictive biomarkers.
Learn More →Whether you need antibodies for research tools, diagnostic assays, or novel therapeutic candidates targeting NY-ESO-1 or other cancer antigens, our integrated platform ensures high-quality and highly specific antibody solutions.
Learn More →Ready to advance your precision oncology initiatives? At Creative Biolabs, we are committed to being your trusted partner in advancing cancer immunotherapy. Our NY-ESO-1 assay portfolio service provides the precision and comprehensive insights necessary to accelerate your research and development efforts. Contact us for more information and to discuss your project.
Reference